

RECEIVED
PRCS
AUG 19 2020
ATTORNEY GENERAL
OF WASHINGTON

BOARD OF TRUSTEES

CHAIRMEN

Paul C. Shiverick
Andrew K. Tsai

VICE CHAIRMEN

Edgar R. Berner
John B. Fitzgibbons
Donald J. Gogel
Jacques C. Nordeman
Andrew M. Paul

TREASURER

Geoffrey O. Coley

SECRETARY

Thomas G. Mendell

Tony Alvarez II
Yacov Arnopolin
Kamini Banga
Peter L. Bloom
Jennifer L. Brorsen
James M. Citrin
W. Robert Dahl
Glenn J. DeSimone
John E. Eckerson
Sean P. Fahey
Margot E. Freedman
Oliver R. Grace Jr.
Sandra Coudert Graham
Michael M. Kellen
Alexander P. Lynch
Michael J. Petrick
Brian Riano
Lief D. Rosenblatt
Frank V. Sica
James A. Stern
Robert S. Stolar
Michael B. Targoff
Diane Tuft
Heidi J. Ueberroth
Lauren S. Veronis
Ronald G. Weiner
Jim Weiss
Peter Zhou

**SCIENTIFIC ADVISORY
COUNCIL**

DIRECTOR

James P. Allison, Ph.D.

ASSOCIATE DIRECTORS

Glenn Dranoff, M.D.
Carl F. Nathan, M.D.
Ellen Puré, Ph.D.
Robert D. Schreiber, Ph.D.
Jedd D. Wolchok, M.D., Ph.D.

**CHIEF EXECUTIVE OFFICER
AND DIRECTOR OF
SCIENTIFIC AFFAIRS**

Jill O'Donnell-Tormey, Ph.D.

FOUNDER

Helen Coley Nauts, D.Sc. (Hon.)
(1907-2001)

FOUNDING CHAIRMAN

Oliver R. Grace
(1909-1992)

**FOUNDING SCIENTIFIC
AND MEDICAL DIRECTOR**

Lloyd J. Old, M.D.
(1933-2011)

August 5, 2020

Attorney General Bob Ferguson
Office of the Attorney General
1125 Washington Street SE
PO Box 40100
Olympia, WA 98504-0100

Re: Notice of Blackbaud Data Security Incident

Dear Attorney General Ferguson:

We are writing pursuant to Wash. Rev. Code §§ 19.255.005-.040 to inform you of a data security incident suffered by one of our third-party service providers that appears to have involved the names and potentially non-public birth dates of approximately 1,312 Washington residents.

We were recently notified by one of our third-party service providers, Blackbaud, Inc. ("Blackbaud"), of a security incident that occurred on its system beginning on February 7, 2020 and continuing through May 20, 2020. Cancer Research Institute ("CRI") is one of many nonprofit organizations that uses Blackbaud as a cloud-based database to research and maintain information about our donors and prospective donors.

Specifically, Blackbaud informed us that in May 2020, it detected and interrupted a ransomware attack. However, before Blackbaud was able to stop this ransomware attack, an unauthorized third party accessed and copied certain data from its system, some of which was unencrypted. Blackbaud has told us that after detecting the attempted ransomware attack, its Cyber Security team—together with independent forensics experts and law enforcement—was able to expel the intruder from Blackbaud's system. Blackbaud reported to us that it paid a ransom in exchange for confirmation that any data that was accessed and copied by the unauthorized third party was destroyed and that it would not be used or disseminated. Blackbaud has told us that it is monitoring for any evidence that the data has been used or made available, and to date, Blackbaud has uncovered no evidence that the data has been made available.

As a client of Blackbaud, we are not privy to the details of the intrusion, the results of its investigation, or the specifics of the information that was accessed by the intruder. Therefore, our understanding of this incident, the information impacted, and Blackbaud's efforts to contain it, is based entirely on information we have received from Blackbaud. Blackbaud has informed us that it has already made enhancements to further improve its data security, and that it continues to monitor the web for any signs that the information accessed during this incident has been misused and to monitor its systems for any suspicious activity.

While all of the details regarding the incident are not available to CRI, we understand that as a result of this incident, some CRI constituents' names were disclosed in connection with partial or full dates of birth that may not be publicly available in government records. This affected approximately 1,312 Washington residents.

SCIENTIFIC ADVISORY COUNCIL

DIRECTOR

James P. Allison, Ph.D.
The University of Texas
MD Anderson Cancer Center

ASSOCIATE DIRECTORS

Glenn Dranoff, M.D.
Novartis Institutes for
BioMedical Research

Carl F. Nathan, M.D.
Weill Cornell Medicine

Ellen Puré, Ph.D.
University of Pennsylvania

Robert D. Schreiber, Ph.D.
Washington University
School of Medicine

Jedd D. Wolchok, M.D., Ph.D.
Memorial Sloan Kettering
Cancer Center

MEMBERS

Frederick W. Alt, Ph.D.
Howard Hughes Medical Institute;
Boston Children's Hospital;
Harvard Medical School

Richard Axel, M.D.
Columbia University Medical Center

Nina Bhardwaj, M.D., Ph.D.
Tisch Cancer Institute, Icahn School
of Medicine at Mount Sinai

Harvey Cantor, M.D.
Dana-Farber Cancer Institute;
Harvard Medical School

Jonathan S. Cebon, Ph.D., FRACP
Olivia Newton-John Cancer
Research Institute; Austin Health

Vincenzo Cerundolo, M.D., Ph.D.
MRC Human Immunology Unit,
University of Oxford

Max D. Cooper, M.D.
Emory University School of Medicine

Lisa M. Coussens, Ph.D.
Oregon Health & Science University

Peter Cresswell, Ph.D.
Yale University School of Medicine

Jason G. Cyster, Ph.D.
University of California, San Francisco

Charles G. Drake, M.D., Ph.D.
Herbert Irving Comprehensive
Cancer Center, NewYork-Presbyterian/
Columbia University Medical Center

Michael L. Dustin, Ph.D.
University of Oxford

Richard A. Flavell, Ph.D., FRS
Yale University School of Medicine

Thomas F. Gajewski, M.D., Ph.D.
The University of Chicago

Laurie H. Glimcher, M.D.
Dana-Farber Cancer Institute

Philip D. Greenberg, M.D.
Fred Hutchinson Cancer
Research Center;
University of Washington
School of Medicine

Axel Hoos, M.D., Ph.D.
GlaxoSmithKline

Patrick Hwu, M.D.
The University of Texas
MD Anderson Cancer Center

Elizabeth M. Jaffee, M.D.
The Sidney Kimmel Comprehensive
Cancer Center, Johns Hopkins University
School of Medicine

Carl H. June, M.D.
Abramson Cancer Center,
Perelman School of Medicine at
the University of Pennsylvania

Susan M. Kaech, Ph.D.
Salk Institute for Biological Studies

Michael Kalos, Ph.D.
Janssen Pharmaceuticals

Michael Karin, Ph.D.
University of California, San Diego

John M. Kirkwood, M.D.
University of Pittsburgh Medical Center
Hillman Cancer Center

Alexander Knuth, M.D.
National Center for Cancer Care and
Research, Hamad Medical Corporation

Lewis L. Lanier, Ph.D.
University of California, San Francisco

Christina S. Leslie, Ph.D.
Memorial Sloan Kettering
Cancer Center

Hyam I. Levitsky, M.D.
Century Therapeutics

Ming O. Li, Ph.D.
Memorial Sloan Kettering
Cancer Center

Dan R. Littman, M.D., Ph.D.
NYU Langone Medical Center

Nils Lonberg, Ph.D.
Canaan Partners

Tak W. Mak, Ph.D., D.Sc., FRSC
The Campbell Family Institute
for Breast Cancer Research
at Princess Margaret Hospital;
University Health Network;
University of Toronto

Philippa C. Marrack, Ph.D.
National Jewish Health; the
University of Colorado Denver

Cornelis J.M. Melief, M.D., Ph.D.
Leiden University Medical Center;
ISA Pharmaceuticals

Ira Mellman, Ph.D.
Genentech

Malcolm A.S. Moore, D.Phil.
Memorial Sloan Kettering
Cancer Center

Lee Nadler, M.D.
Dana-Farber Cancer Institute;
Harvard Medical School

Kunle Odunsi, M.D., Ph.D.
Roswell Park Comprehensive
Cancer Center

Drew M. Pardoll, M.D., Ph.D.
The Sidney Kimmel Comprehensive
Cancer Center, Johns Hopkins University
School of Medicine

Klaus Rajewsky, M.D.
Max Delbrück Center
for Molecular Medicine

Anjana Rao, Ph.D.
La Jolla Institute for Allergy and
Immunology; Sanford Consortium
for Regenerative Medicine

Stanley R. Riddell, M.D.
Fred Hutchinson Cancer
Research Center;
University of Washington
School of Medicine

Alexander Y. Rudensky, Ph.D.
Memorial Sloan Kettering
Cancer Center

Bijan Safai, M.D., D.Sc.
New York Medical College

Shimon Sakaguchi, M.D., Ph.D.
Immunology Frontier Research
Center, Osaka University

Lawrence E. Samelson, M.D.
National Cancer Institute, NIH

Hans Schreiber, M.D., D.MSc., Ph.D.
The University of Chicago

Ton N. Schumacher, Ph.D.
The Netherlands Cancer Institute

Craig L. Slingluff Jr., M.D.
University of Virginia School of Medicine

Mark J. Smyth, Ph.D., FAHMS
QIMR Berghofer Medical
Research Institute

Pramod K. Srivastava, M.D., Ph.D.
Carole and Ray Neag Comprehensive
Cancer Center at UConn Health

Susumu Tonegawa, Ph.D.
Massachusetts Institute of Technology

Giorgio Trinchieri, M.D.
National Cancer Institute, NIH

Emil R. Unanue, M.D.
Washington University School
of Medicine

Ulrich H. von Andrian, M.D., Ph.D.
Harvard Medical School;
The Ragon Institute of MGH,
MIT and Harvard

Robert H. Vonderheide, M.D., D.Phil.
Abramson Cancer Center,
Perelman School of Medicine at
the University of Pennsylvania


E. John Wherry, Ph.D.
Perelman School of Medicine at
the University of Pennsylvania

Hao Wu, Ph.D.
Boston Children's Hospital;
Harvard Medical School

Kai W. Wucherpfennig, M.D., Ph.D.
Dana-Farber Cancer Institute

Cassian Yee, M.D.
The University of Texas
MD Anderson Cancer Center

Rolf M. Zinkernagel, M.D., Ph.D.
University of Zürich



CANCER
RESEARCH
INSTITUTE

The Leader in Immunotherapy


No other personal information that is defined as “personal information” under RCW 19.255.010 was included in the accessed data as far as we know at this time. However, the data copied may have contained information such as a donor’s mailing address and history of giving to CRI as of February 2020.

Concurrently with the filing of this letter, we are sending notifications to affected individuals. A copy of the notification letter is attached.

CRI remains committed to ensuring the security and privacy of its constituents’ information.

Please do not hesitate to contact Alfred R. Massidas, Chief Financial Officer, at (212) 688-7515 x 237 or amassidas@cancerresearch.org if you have any questions.

Sincerely,



Jill O'Donnell-Tormey, Ph.D.
Chief Executive Officer and Director of Scientific Affairs



**CANCER
RESEARCH
INSTITUTE®**

The Leader in Immunotherapy

BOARD OF TRUSTEES

CHAIRMEN

Paul C. Shiverick
Andrew K. Tsai

VICE CHAIRMEN

Edgar R. Berner
John B. Fitzgibbons
Donald J. Gogel
Jacques C. Nordeman
Andrew M. Paul

TREASURER

Geoffrey O. Coley

SECRETARY

Thomas G. Mendell

Tony Alvarez II
Yacov Aronopolin
Kamini Banga
Peter L. Bloom
Jennifer L. Brorsen
James M. Citrin
W. Robert Dahl
Glenn J. DeSimone
John E. Eckerson
Sean P. Fahey
Margot E. Freedman
Oliver R. Grace Jr.
Sandra Coudert Graham
Michael M. Kellen
Alexander P. Lynch
Michael J. Petrick
Brian Riano
Lief D. Rosenblatt
Frank V. Sica
James A. Stern
Robert S. Stolar
Michael B. Targoff
Diane Tuft
Heidi J. Ueberroth
Lauren S. Veronis
Ronald G. Weiner
Jim Weiss
Peter Zhou

**SCIENTIFIC ADVISORY
COUNCIL**

DIRECTOR

James P. Allison, Ph.D.

ASSOCIATE DIRECTORS

Glenn Dranoff, M.D.
Carl F. Nathan, M.D.
Ellen Puré, Ph.D.
Robert D. Schreiber, Ph.D.
Jedd D. Wolchok, M.D., Ph.D.

**CHIEF EXECUTIVE OFFICER
AND DIRECTOR OF
SCIENTIFIC AFFAIRS**

Jill O'Donnell-Tormey, Ph.D.

FOUNDER

Helen Coley Nauts, D.Sc. (Hon.)
(1907-2001)

FOUNDING CHAIRMAN

Oliver R. Grace
(1909-1992)

**FOUNDING SCIENTIFIC
AND MEDICAL DIRECTOR**

Lloyd J. Old, M.D.
(1933-2011)

August 5, 2020

Name

Address

Re: Notice of Blackbaud Data Security Incident

Dear Salutation,

We are writing to let you know about a data security incident suffered by one of our third-party service providers that involved your personal information. Pursuant to Washington State law, Wash. Rev. Code §§ 19.255.005–.040, notice is required in the event that certain non-public personal information about Washington residents, including name together with date of birth, is compromised. More details are below, but please note that no credit card data, bank account information, or social security numbers were accessed in this incident. We are grateful for your support of the Cancer Research Institute (“CRI”), and we provide this notice to you to explain what happened and how you can protect yourself.


What Happened

We were recently notified that Blackbaud, Inc., a provider of cloud-based data management services to CRI and many other nonprofit organizations, experienced a ransomware attack earlier this year. As a client of Blackbaud, we are not privy to all details of the intrusion or the results of Blackbaud’s investigation. Therefore, our understanding of this incident, the information impacted, and Blackbaud’s efforts to contain it, is based entirely on information we have received from Blackbaud.

We understand from Blackbaud that the incident began on February 7, 2020 and is believed to have continued through May 20, 2020, when Blackbaud expelled the attacker from its systems. In this ransomware attack, an unauthorized third party accessed and copied a subset of data stored on Blackbaud’s systems and demanded a ransom payment in exchange for destroying that information. This data included certain information that CRI maintains on a Blackbaud platform regarding our constituents. Blackbaud has advised us that it paid a ransom in exchange for confirmation from the unauthorized third-party that any data that was accessed and copied has been destroyed. Additionally, Blackbaud reports that it is actively monitoring via third party experts and has found no trace of the data on the web. We have no reason to believe at this point that your information was actually used by, or will be disseminated by, the unauthorized third-party.

What information Was Involved

There was no unauthorized access to your credit card data or bank account information as part of this incident. We do not use Blackbaud to process financial transactions, and Blackbaud has



**CANCER
RESEARCH
INSTITUTE**

The Leader in Immunotherapy

confirmed that no credit card data, bank account information, usernames, passwords, or social security numbers were accessed more generally. However, we have determined that the data which was copied contained certain

information about you, including your name and full or partial date of birth, and may have also contained information such as your mailing address and history of giving to CRI as of February 2020.

What We Are Doing

CRI takes the protection and proper use of your personal information very seriously. Blackbaud has informed us that the ransomware attack has been fully contained and that its system has been secured. Blackbaud has informed us that it has already made enhancements to further improve its data security, and that it continues to monitor the web for any signs that the information accessed during this incident has been misused and to monitor its systems for any suspicious activity. We have communicated our disappointment regarding this incident to Blackbaud, and we continue to investigate to confirm and better understand what occurred. We are notifying you of this incident so that you can take action to protect yourself.

What You Can Do

Although we currently have no evidence that your personal information will be misused, we encourage you to remain vigilant and promptly report to us and to the proper law enforcement authorities if you notice any suspicious activity or suspected misuse of your personal information. As a general practice, we recommend that you carefully check your credit reports for accounts you did not open or for inquiries from creditors you did not initiate. Contact information for the major credit reporting agencies is included here:

Equifax
P.O. Box 740256
Atlanta, GA 30374
(866) 349-5191
www.equifax.com

Experian
P.O. Box 4500
Allen, TX 75013
(888) 397-3742
www.experian.com

TransUnion
P.O. Box 2000
Chester, PA 19016
(855) 681-3196
www.transunion.com

You should regularly review your credit or debit card account statements to determine if there are any discrepancies or unusual activity listed. If you see something you do not recognize, immediately notify your financial institution.

For More Information

We appreciate your support of our work, and we regret any inconvenience this may cause you. Should you have any further questions or concerns regarding this matter and/or the protections available to you, please do not hesitate to contact Alfred R. Massidas at (212) 688-7515 x 237 or amassidas@cancerresearch.org.

Sincerely,

Jill O'Donnell-Tormey, Ph.D.
Chief Executive Officer and Director of Scientific Affairs